Novasep announced a strategic investment of US$30 million for a commercial scale production facility of viral vectors.
The new facility will be built at Novasep in Seneffe, Belgium to complement the existing lab-scale suites of the neighbouring site in Gosselies.
The site will feature two cGMP suites on 2000 sqm equipped with a set of single-use bioreactors ranging from 200L up to 2000L. It will fit perfectly with the production requirements for phase III and commercial stages.
To make each project specific, many types of viral vectors are currently being developed. The plant is a response to the strong market demand driven by both a growing interest in this therapeutic approach and a maturing clinical pipeline.
The viral vectors are used in gene therapies or immunotherapies such as new cancer treatment strategies and in new generation therapeutic vaccines.
Nearly 300 products in clinical studies and 9 products are launched into the market by the facility.
The therapeutic approach consists in using the ability of a virus to introduce the genetic material into the host cell. With viral vectors, the genetic material is modified in order to repair the host cell. Typical viral vectors are Lentiviruses, Adenoviruses, and Adeno-associated viruses.
These innovative therapies require targeted technologies for their production.